Literature DB >> 28611201

Relationship of the Breast Ductal Carcinoma In Situ Immune Microenvironment with Clinicopathological and Genetic Features.

Shona Hendry1,2,3, Jia-Min B Pang1,2, David J Byrne1, Sunil R Lakhani4,5,6, Margaret C Cummings4,5,6, Ian G Campbell2,7,8, G Bruce Mann9, Kylie L Gorringe10,7,8, Stephen B Fox1,2.   

Abstract

Purpose: The immune microenvironment of breast ductal carcinoma in situ (DCIS) has yet to be fully explored, and the relationship of immune cells to genetic features of DCIS is unknown.Experimental Design: We quantified tumor associated lymphocytes (TIL) and evaluated PD-L1 protein levels by immunohistochemistry in a cohort of pure DCIS (138 and 79 cases, respectively), some of which had copy number (n = 55) and mutation data (n = 20).
Results: TILs were identified in the stroma surrounding DCIS (119/138, 86%) and present at a median TIL score of 5% (range, 0%-90%). Most DCIS were negative for tumor cell PD-L1 staining (89%), but 25% of cases were positive for immune cell staining. We observed that, as in invasive breast cancer, TILs and PD-L1 positivity were significantly greater in high-grade (P = 0.002/0.035), ER-negative (P = 0.02/0.02), and ERBB2-amplified tumors (P < 0.001/0.048). Comedo necrosis was significantly positively associated with TILs (P < 0.0001) but not with PD-L1. The TILs score was significantly higher in cases with TP53 mutation (P = 0.03) but not with PIK3CA or GATA3 mutation. In the cases with copy number data, both the fraction of the genome altered and the number of telomeric imbalances were significantly positively correlated with TILs (both P < 0.001). This result strongly contrasted with invasive breast cancer data, where aneuploidy was not correlated to TIL levels.Conclusions: Although a small cohort, our data suggest a preliminary model by which the progression of DCIS to invasive carcinoma may involve an altered relationship of tumor copy number with the immune microenvironment, possibly by the immunoediting of the tumor. Clin Cancer Res; 23(17); 5210-7. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28611201     DOI: 10.1158/1078-0432.CCR-17-0743

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  24 in total

Review 1.  Ductal carcinoma in situ of breast: update 2019.

Authors:  Sunil S Badve; Yesim Gökmen-Polar
Journal:  Pathology       Date:  2019-08-28       Impact factor: 5.306

Review 2.  Ductal Carcinoma In Situ of Breast: From Molecular Etiology to Therapeutic Management.

Authors:  Shelby Lynn Hophan; Olena Odnokoz; Huiping Liu; Yuan Luo; Seema Khan; William Gradishar; Zhuan Zhou; Sunil Badve; Mylin A Torres; Yong Wan
Journal:  Endocrinology       Date:  2022-04-01       Impact factor: 4.736

Review 3.  Ductal Carcinoma in Situ: Molecular Changes Accompanying Disease Progression.

Authors:  Gemma M Wilson; Phuong Dinh; Nirmala Pathmanathan; J Dinny Graham
Journal:  J Mammary Gland Biol Neoplasia       Date:  2022-05-14       Impact factor: 2.698

Review 4.  Learning to distinguish progressive and non-progressive ductal carcinoma in situ.

Authors:  Anna K Casasent; Mathilde M Almekinders; Charlotta Mulder; Proteeti Bhattacharjee; Deborah Collyar; Alastair M Thompson; Jos Jonkers; Esther H Lips; Jacco van Rheenen; E Shelley Hwang; Serena Nik-Zainal; Nicholas E Navin; Jelle Wesseling
Journal:  Nat Rev Cancer       Date:  2022-10-19       Impact factor: 69.800

5.  Ductal carcinoma in situ of the breast: immune cell composition according to subtype.

Authors:  Marie Colombe Agahozo; Mieke R van Bockstal; Floris H Groenendijk; Thierry P P van den Bosch; Pieter J Westenend; Carolien H M van Deurzen
Journal:  Mod Pathol       Date:  2019-08-02       Impact factor: 7.842

Review 6.  Breaking through to the Other Side: Microenvironment Contributions to DCIS Initiation and Progression.

Authors:  Andrew C Nelson; Heather L Machado; Kathryn L Schwertfeger
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-08-31       Impact factor: 2.673

7.  Breast ductal Carcinoma in situ associated with microinvasion induces immunological response and predicts ipsilateral invasive recurrence.

Authors:  Xiao-Yang Chen; Aye Aye Thike; Valerie Cui Yun Koh; Nur Diyana Md Nasir; Boon Huat Bay; Puay Hoon Tan
Journal:  Virchows Arch       Date:  2020-11-02       Impact factor: 4.064

8.  Genomic Alterations during the In Situ to Invasive Ductal Breast Carcinoma Transition Shaped by the Immune System.

Authors:  Anne Trinh; Carlos R Gil Del Alcazar; Sachet A Shukla; Koei Chin; Young Hwan Chang; Guillaume Thibault; Jennifer Eng; Bojana Jovanović; C Marcelo Aldaz; So Yeon Park; Joon Jeong; Catherine Wu; Joe Gray; Kornelia Polyak
Journal:  Mol Cancer Res       Date:  2020-12-18       Impact factor: 6.333

9.  Single-Cell Sequencing Identifies the Heterogeneity of CD8+ T Cells and Novel Biomarker Genes in Hepatocellular Carcinoma.

Authors:  Hailei Wang; Yang Fu; Bin-Bin Da; Geng Xiong
Journal:  J Healthc Eng       Date:  2022-04-12       Impact factor: 3.822

Review 10.  The Immune Microenvironment and Cancer Metastasis.

Authors:  Asmaa El-Kenawi; Kay Hänggi; Brian Ruffell
Journal:  Cold Spring Harb Perspect Med       Date:  2020-04-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.